For its fourth fiscal quarter (ending December 31), BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported E.P.S. of $-0.31 compared to $-0.38 a year ago. This performance was $-0.08 short of the consensus estimate of $-0.23. E.P.S. were $-1.18 for the latest four quarters through December 31 versus $-1.33 for the same period a year ago.
Recent Price Action
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock increased 1.4% on 2/26/24. The shares closed at $5.79. Moreover, this advance was accompanied by above average trading volume at 124% of normal. The stock has been weak relative to the market over the last nine months but has risen 2.7% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment